Physician profile
Timothy Lee Light
NPI 1912215807
$10,077.30
in general payments reported to CMS, 2019-2025
46 companies · $1,186 in 2025
The $1,186 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $776 · 2021: $1,699 · 2022: $1,312 · 2023: $3,488 · 2024: $1,145 · 2025: $1,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,120 · Travel and Lodging: $1,699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,120.18 |
| Travel and Lodging | $1,698.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $2,067.72 | 2023 | |
| Lilly USA, LLC | $924.28 | 2020-2025 | Mounjaro, Reyvow, Emgality |
| Abbvie INC. | $849.30 | 2021-2025 | |
| Novo Nordisk INC | $733.34 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $693.38 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $558.57 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $366.14 | 2021-2025 | Airsupra, Breztri, Fasenra |
| Amgen INC. | $312.12 | 2019-2025 | Repatha, Otezla, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $310.36 | 2019-2025 | Xifaxan |
| Abbott Laboratories | $286.80 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $262.38 | 2020-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.72 | 2020-2025 | Jardiance |
| Amarin Pharma, INC. | $220.57 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $205.22 | 2021 | |
| Mylan Specialty L.P. | $193.83 | 2020-2023 | Yupelri |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $183.65 | 2019-2023 | |
| Esperion Therapeutics, INC. | $142.29 | 2020-2025 | Nexletol |
| Biohaven Pharmaceutical Holding Company Ltd. | $137.38 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.32 | 2021-2025 | Hyqvia |
| Astellas Pharma US INC | $118.53 | 2023-2025 | Veozah, Myrbetriq |
| Lundbeck LLC | $107.61 | 2021-2025 | Vyepti, Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $103.42 | 2023-2025 | |
| Lucid Diagnostics INC. | $79.90 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $67.45 | 2024 | Voquezna |
| Exact Sciences Corporation | $66.12 | 2025 | Cologuard Collection Kit |
| Eisai INC. | $62.54 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $58.34 | 2021 | |
| Tersera Therapeutics LLC | $55.18 | 2022-2025 | Quzyttir |
| Boston Scientific Corporation | $54.34 | 2024-2025 | General - Pain Management, General - Atherectomy, Watchman Access System |
| Csl Behring | $53.89 | 2022-2024 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $47.38 | 2019-2021 | |
| Allergan, INC. | $44.46 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $41.38 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $38.63 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $36.09 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $33.64 | 2022-2023 | Quviviq |
| Blueprint Medicines Corporation | $29.44 | 2025 | Ayvakit |
| Upsher-Smith Laboratories LLC | $27.22 | 2020 | |
| Paratek Pharmaceuticals, INC. | $24.02 | 2021 | |
| Axsome Therapeutics, INC. | $23.35 | 2025 | Symbravo |
| Renalytix Ai, INC. | $22.13 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Inogen, INC. | $21.53 | 2022 | |
| Melinta Therapeutics, LLC | $15.68 | 2019 | |
| Inari Medical, INC. | $14.95 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Dexcom, INC. | $14.14 | 2024 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $13.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Light listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.